A Study of the Pan-KRAS Inhibitor LY4066434 in Participants With KRAS Mutant Solid Tumors
Eli Lilly and Company
Eli Lilly and Company
Kumquat Biosciences Inc.
National Institutes of Health Clinical Center (CC)
Seagen Inc.
Seagen Inc.
Pliant Therapeutics, Inc.
Eli Lilly and Company
BioNTech SE
Eli Lilly and Company
University of Pittsburgh
Kivu Bioscience Inc.
Instil Bio
AstraZeneca
National Institutes of Health Clinical Center (CC)
SWOG Cancer Research Network
National Cancer Institute (NCI)
Bristol-Myers Squibb
Travera Inc
Eli Lilly and Company
OncoC4, Inc.
Jazz Pharmaceuticals
Revolution Medicines, Inc.
Exscientia AI Limited
Amgen
USWM, LLC (dba US WorldMeds)
Genmab
Seagen Inc.
KaliVir Immunotherapeutics
Fate Therapeutics
National Institutes of Health Clinical Center (CC)
EMD Serono
Arcus Biosciences, Inc.
IDEAYA Biosciences
Agenus Inc.
Radiopharm Theranostics, Ltd
Sotio Biotech Inc.
Radiopharm Theranostics, Ltd
Whitehawk Therapeutics, Inc.
National Cancer Institute (NCI)
GlaxoSmithKline
Rondo Therapeutics
Orano Med LLC
Wake Forest University Health Sciences
Dragonfly Therapeutics
Merck Sharp & Dohme LLC
Eisai Inc.
Fondazione del Piemonte per l'Oncologia
PMV Pharmaceuticals, Inc
Mayo Clinic
Mayo Clinic